ClinicalTrials.gg
RecruitingNCT05460000N-PlusUpdated Oct 23, 2026

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

A Phase 2 interventional study of 3 cycles chemotherapy instead of 6 cycles chemotherapy and 6 cycles chemotherapy in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by North Eastern German Society of Gynaecological Oncology. Recruiting at 50 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by North Eastern German Society of Gynaecological Oncology · Phase 2, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 23, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Ovarian Neoplasms by North Eastern German Society of Gynaecological Oncology — 1 open to participants now, 2 under way, none of them phase 3. Ovarian Neoplasms · North Eastern German Society of Gynaecological Oncology.

Planned enrollment
Largest of 12
640 · median 114
Started
2024
the only one that year
Phase 2
6 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Ovarian Neoplasms by North Eastern German Society of Gynaecological Oncology, this one has the largest planned enrollment, is the only one that started in 2024, is one of 6 in phase 2, and was the 12th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 12 studies in Ovarian Neoplasms by North Eastern German Society of Gynaecological Oncology is open now, in 6 countries.

By country, each count listing its studies:

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ovarian Neoplasms by North Eastern German Society of Gynaecological Oncology, or all of them as a file.
02

Study summary

Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.

Read the detailed description

This is a multicenter, randomized, open label study including patients with advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking.

The main scope of the trial is to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.

Patients will be randomized 1:1 to receive either 3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (Arm A) or 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (Arm B). Randomization will be performed according to the results of the NGS analysis and stratified either to BRCAm independent of LOH or LOHhigh/ BRCAwt, FIGO stage III vs. IV, and countries. In both of the arms, tumor assessments (CT or MRI) will be performed 9-12 weeks after the start of therapy (after 3rd cycle of chemotherapy), after another 9-12 weeks (during maintenance therapy in Arm A and after the 6th cycle of chemotherapy in Arm B) and every 6 months thereafter. The tumor marker CA-125 will be assessed every 12 weeks in both arms.

During chemotherapy treatment, clinical visits (blood cell counts, detection of toxicity) occur at least every 3 weeks (depending on the chemotherapy regimen). Serum pregnancy tests for WOCBP occur at least every 4 weeks. During maintenance therapy with niraparib, clinical visits (blood cell counts, detection of toxicity) occur every 4 weeks for the first 11 months and every 12 weeks thereafter. Serum pregnancy tests for WOCBP occur at least every 4 weeks. Complete physical examinations will take place every 12 weeks. Safety will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs).

About 60 sites in 6 European countries will participate in this study to recruit 640 patients in 36 months.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
  • Clear Cell Carcinoma

Keywords

  • maintenance therapy
  • niraparib
  • HRDpositive
  • R0
  • primary tumor debulking
  • chemotherapy
  • LOH
  • carboplatin
  • paclitaxel
  • first line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  2. Female patient, age ≥ 18 years.
  3. FIGO Stage III-IV high-grade ovarian cancer (all histological types, except mucinous histology)
  4. Complete primary debulked patients (without any macroscopic residuals), confirmed by CT-Scan postoperatively.
  5. Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary cancer for central NGS analysis and must be HRDpositive defined as BRCAmut independent of NOGGO GIS Score OR NOGGO GIS Score >83 independent of BRCA status, based on these results.
  6. (ECOG) performance status 0 or 1.
  7. Patients must be able to take oral medications.
  8. Synchronous and secondary are allowed if the prognosis of the ovarian cancer is not affected. The investigator must contact the medical monitoring team before enrolling the patient in the clinical trial.
  9. Patients must have normal organ and bone marrow function:

    1. ≥ 10.0 g/dL independent of transfusion ≤ 14 days prior to screening hemoglobin assessment
    2. (ANC) ≥ 1.5 x 109/L
    3. count ≥ 100 x 109/L
    4. Total ≤ 1.5 x institutional (ULN); \< 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome
    5. /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2,5 x ULN
    6. Serum creatinine ≤ 1.5 x institutional ULN and > 30 mL/min.
  10. or evidence of non-childbearing status for women of prior to the first dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test result ≤3 days prior to administration of the first dose of study treatment.

Patients are considered to be of childbearing potential unless 1 of the following applies:

  1. Considered to be permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy; or
  2. Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 mIU/mL or higher) may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state.

Female patients of must practice highly effective methods (failure rate \< 1% per year) of contraception with their partners, if of reproductive potential, during treatment and for 6 months following the last dose of chemotherapy or the last dose of niraparib, whichever occurs later, or longer if requested by local authorities. Highly effective contraception includes: Ongoing use of progesterone only injectable or implantable contraceptives; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Bilateral tubal occlusion; Sexual abstinence as defined as complete or true abstinence, acceptable only when it is the usual and preferred lifestyle of the patient; periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not acceptable; or Sterilization of the male partner, with appropriate post-vasectomy documentation of absence of sperm in ejaculate.

Exclusion criteria

Exclusion Criteria:

  1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e., germ cell tumors) and Ovarian tumors of low malignant potential (e.g., borderline tumors), or mucinous carcinoma of the ovary.
  2. Low-grade ovarian, fallopian tube or peritoneal cancer.
  3. Has known to any of the study drugs or any of the of any of the study drugs.
  4. Has known hypersensitivity to platin-containing compounds other than carboplatin.
  5. Patients posttransplant, including previous bone marrow transplant.
  6. Has undergone interval debulking of the tumor.
  7. Has received any anti-cancer therapy for ovarian cancer other than primary surgery.
  8. Administration of other simultaneous chemotherapy drugs, any other anti-cancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).
  9. Has received prior treatment with a PARP inhibitor or has participated in a trial where any treatment arm included the administration of a PARP inhibitor.
  10. Bevacizumab is planned to be given together with chemotherapy or as maintenance.
  11. cardiovascular disease:

    1. Cerebrovascular accident or myocardial infarction or unstable angina ≤6 months before start of study treatment
    2. Severe cardiac arrhythmia (recent event or active or uncontrolled)
    3. grade ≥2 congestive heart failure
    4. Uncontrolled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy or posterior reversible encephalopathy syndrome
    5. History of stroke or ≤6 months before start of study treatment
    6. Coronary/peripheral artery bypass graft ≤6 months before start of study treatment
    7. Deep vein thrombosis or thromboembolic events ≤1 month before start of study treatment
  12. History or evidence of or spinal cord compression.
  13. Known history of MDS or a pre-treatment cytogenetic testing result at risk for a diagnosis of MDS/AML.
  14. Current, clinically relevant bowel obstruction at the time of randomization.
  15. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  16. Pregnant or lactating women, women of who do not agree to the usage of highly effective methods (see inclusion criteria) starting with the screening visit through at least 6 months after the last dose of chemotherapy treatment or through at least 1 month after the last dose of niraparib, whichever occurs later.
  17. Participation in another clinical study with an product immediately prior to randomization. Earliest time point for randomization is after the time required for the investigational product to undergo 5 half-lives has passed.
  18. Has a known history of (HIV) infection (known HIV1/HIV2 antibodies positive) or acquired immunodeficiency syndrome (AIDS) related illness.
  19. Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] has been detected) infection.
  20. Has active infection with SARS-CoV-2 (antigen test).
  21. Has received a or live-attenuated vaccine within 30 days prior to the first dose of chemotherapy treatment and while and 28 days after the last dose of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Administration of inactivated vaccines is allowed.
  22. Patient has listed in the most recent SmPC.
  23. Patient who might be dependent on the sponsor, CRO, site or the investigator.

22. In Germany: Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40a S. 1 Nr. 2 AMG.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
640 participants (estimated)

Study arms

  • Experimental
    Arm A (3 cycles of chemotherapy + maintenance therapy with niraparib)

    3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.

    Drug: 3 cycles chemotherapy instead of 6 cycles chemotherapy

  • Active comparator
    Arm B (6 cycles of chemotherapy + maintenance therapy with niraparib)

    6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.

    Drug: 6 cycles chemotherapy

Interventions

  • Drug3 cycles chemotherapy instead of 6 cycles chemotherapy

    We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.

  • Drug6 cycles chemotherapy

    Standard chemotherapy as comparator

This study also gives NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. RFS

    Recurrence free survival, defined as time from treatment randomization to the earliest date of assessment of first relapse or death by any cause

    Time frame: 8 years

Secondary outcomes

  1. Overall survival (OS)

    time to event and rate at 3 and 5 years

    Time frame: 8 years

  2. TFST

    Time to first subsequent treatment

    Time frame: 8 years

  3. TWIST (Time Without Symptoms of disease progression or Toxicity of treatment)

    at baseline, 3, 6, and 12 months

    Time frame: 8 years

  4. PFS2

    Time from randomization until the date of second objective disease progression or death by any cause

    Time frame: 8 years

  5. Quality of Life (QoL) 1

    Patients are asked to answer the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30). Responses of questions 1-28 are based on a 4-point scale (1=not at all; 4=Very much), with a higher score indicating a high degree of symptomatology and must therefore be assessed negatively. Responses of questions 29 and 30 are based on a 7-point scale (1=Very poor; 7=Excellent), with a higher score indicating a better global health status.

    Time frame: 8 years

  6. Quality of Life 2

    Patients are asked to answer the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28). Responses are based on a 4-point scale (1=Not at all; 4=Very much), with a lower score indicating better symptoms.

    Time frame: 8 years

  7. Quality of Life/ Global health status 3

    Patients are asked to answer the short version of the SF-36 Health Survey (SF-12). The questionnaire contains a total of 12 questions with different response options. For questions 1, 8 and 12 there are 5 (1=excellent, 5=bad), for question 2-3 there are 3 (1=yes, very restricted, 3=no, not restricted at all) and for questions 9-11 there are 6 response options (1= always, 6 = never). Questions 4-7 can be answered with "Yes" or "No".

    Time frame: 8 years

  8. Safety Endpoints - safety of therapy (3 vs. 6 cycles of chemotherapy + niraparib maintenance therapy) according to CTCAE 5.0 criteria will be used as endpoint

    The safety objective is to characterize the safety and tolerability of 3 vs. 6 cycles of chemotherapy followed by maintenance therapy with niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking. The following safety parameters will be analyzed: adverse events and serious adverse events graded per NCI CTCAE, Version 5.0 criteria with time to onset/recovery, causality and outcome; changes in laboratory values, vital signs since baseline, treatment discontinuations and reason for discontinuation, death and cause of death etc. concomitant medications will be collected with time and reasons of use. These are routine safety parameters collected and analyzed in Phase II /III oncology trials.

    Time frame: 8 years

  9. Cost effectiveness

    The objective is to show that less cycles of chemotherapy are as efficient and at the same time less toxic. Additional cycles of chemotherapy significantly increase toxicity and therefore lead to an increase of costs regarding, e.g. in-patient treatment, concomitant medications to treat (S)AEs.

    Time frame: 8 years

07

Study locations

31 of 50 sites recruiting
  • Universitätsklinik Innsbruck
    Innsbruck, 6020, Austria
    Recruiting
    • Christian Marth, Prof. Dr. · Contact
  • Cliniques Universitaires St. Luc
    Brussels, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UZ Gent
    Ghent, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jessa ziekenhuis
    Hasselt, Belgium
    Recruiting
    • Eric Joosens, MD · Contact
  • UZ Leuven
    Leuven, Belgium
    Recruiting
    • Toon Van Gorp, Prof. Dr. · Contact
  • University Hospital Ostrava
    Ostrava, Czechia
    Recruiting
    • Jan Kümmel, MD · Contact
  • General University Hospital in Prague
    Prague, Czechia
    Recruiting
    • Filip Frühauf, MD · Contact
  • University Hospital Bulovka
    Prague, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Aachen
    Aachen, 52074, Germany
    Recruiting
    • Philipp Meyer-Wilmes, Dr. · Contact
    • Elmar Stickeler, Prof. Dr. · Sub investigator
  • Klinikum Mittelbaden Baden-Baden Bühl
    Baden-Baden, Germany
    Not yet recruiting
    • Antje Hahn, Dr. · Contact
    • Uwe Cramer · Sub investigator
  • DRK-Kliniken Berlin-Köpenick
    Berlin, 12559, Germany
    Recruiting
    • Jessika Goldmann, Dr. · Contact
    • Rainer Wieth, Dr. · Sub investigator
  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
    Berlin, 13353, Germany
    Recruiting
    • Jalid Sehouli, Prof. Dr. · Contact
    • Elena Ioana Braicu, Prof. Dr. · Sub investigator
    • Klaus Pietzner, Prof. Dr. · Sub investigator
    • Radoslav Chekerov, PD Dr. · Sub investigator
  • ZAHO Bonn Onkologische Praxis
    Bonn, 53115, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Uniklinikum Bonn
    Bonn, Germany
    Recruiting
    • Alexander Mustea, Prof. Dr. · Contact
    • Lucia A Otten, Dr. · Sub investigator
  • Universitätsklinikum Köln
    Cologne, Germany
    Recruiting
    • Florin-Andrei Taran, Prof. Dr. · Contact
    • Christian Maurer · Sub investigator
  • Klinikum Lippe
    Detmold, Germany
    Recruiting
    • Beyhan Ataseven, Prof. Dr. · Contact
    • Nina Pauly, Dr. · Sub investigator
  • Klinikum Dortmund - Klinikum der Universität Witten Herdecke
    Dortmund, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
    Recruiting
    • Pauline Wimberger, Prof. Dr. · Contact
    • Theresa Link, Dr. · Sub investigator
  • Florence-Nightingale-Krankenhaus Düsseldorf-Kaiserswerth
    Düsseldorf, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Freiburg
    Freiburg im Breisgau, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinik Göttingen
    Göttingen, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • SLK-Kliniken Heilbronn
    Heilbronn, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Schleswig-Holstein Campus Kiel
    Kiel, Germany
    Recruiting
    • Sandra Brügge, Dr. · Contact
    • Katja Rieke, Dr. · Sub investigator
  • Universitätsklinikum Leipzig
    Leipzig, Germany
    Recruiting
    • Bahriye Aktas, Prof. Dr. · Contact
    • Christiane Weisgerber · Sub investigator
  • Universitätsklinik der Johannes-Gutenberg Universität Mainz
    Mainz, 55131, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Klinikum Dritter Orden
    München, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Diakonie Klinikum Schwäbisch Hall
    Schwäbisch Hall, Germany
    Recruiting
    • Suzana Mittelstadt · Contact
    • Marie-Therese Bender, Dr. · Sub investigator
  • Christliches Klinikum Unna Mitte
    Unna, 59423, Germany
    Recruiting
    • Cosmin-Paul Sarac, Dr. · Contact
    • Christin Kühn, Dr. · Sub investigator
  • Helios Dr. Horst Schmidt Kliniken Wiesbaden
    Wiesbaden, 65199, Germany
    Recruiting
    • Michael Eichbaum, Prof. Dr. · Contact
    • Tatjana Cordes, Dr. · Sub investigator
  • Policlinico St. Orsola Malpighi
    Bologna, Italy
    Recruiting
    • Claudio Zamagni · Contact
  • ASST Spedali Civili di Brescia
    Brescia, Italy
    Recruiting
    • Valentina Zizioli, Dr. · Contact
  • ASST Lecco - Ospedale A. Manzoni
    Lecco, Italy
    Recruiting
    • Antonio Ardizzoia, Dr. · Contact
  • IRCCS Istituto nazionale dei Tumori
    Milan, Italy
    Recruiting
    • Francesco Raspagliesi, MD · Contact
  • AOU Cagliari
    Monserrato, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Istituto Oncologico Veneto (IOV)
    Padova, Italy
    Recruiting
    • Giulia Tasca, MD · Contact
  • Azienda Ospedaliera Universitaria Pisana
    Pisa, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda USL IRCCS Di Reggio Emilia
    Reggio Emilia, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AO Ordine Mauriziano
    Torino, Italy
    Recruiting
    • Annamaria Ferrero, MD · Contact
  • AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna
    Torino, Italy
    Recruiting
    • Dionyssios Katsaros · Contact
  • Hospital General Universitario Dr. Balmis
    Alicante, Spain
    Recruiting
    • Inmaculada Lozano · Contact
  • Hospital Virgen de las Nieves
    Granada, Spain
    Recruiting
    • Lucía Castillo Portellano · Contact
  • Hospital Universitario Lucus Augusti
    Lugo, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CIOCC Clara Campal
    Madrid, Spain
    Recruiting
    • Arantzazu Barquin · Contact
  • H. Althaia Manresa
    Manresa, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • H.U. Virgen de la Macarena
    Seville, Spain
    Recruiting
    • Maria del Mar Gordón · Contact
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
    Recruiting
    • Purificación Estevez · Contact
  • Hospital Universitario Sant Joan de Reus
    Tarragona, Spain
    Recruiting
    • Maria Masvidal Hernánez · Contact
  • Hospital General Universitario de Valencia
    Valencia, Spain
    Recruiting
    • Cristina Caballero Díaz · Contact
  • Hospital La Fe
    Valencia, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Sehouli J, Pietzner K, Zocholl D, Nguyen J, Leitner K, Eichbaum M, Goldmann J, Fruhauf F, Van Gorp T, Estevez-Garcia P, Katsaros D, Braicu EI. A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62). Int J Gynecol Cancer. 2026 May 15:104557. doi: 10.1016/j.ijgc.2026.104557. Online ahead of print. PubMed 42140839 ↗

Individual participant data

Plan to share: Yes — Scientists may submit a request for scientific use of the data after the first publication. This request shall be examined by the working group and the leading PI. After signing an agreement, the anonymous data can be made available to the scientist (password protected).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2032, 95 months after the start.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's planned 95 months is above that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2022
First posted
Jul 15, 2022
StartActual
Oct 11, 2024
Primary completionEst.
Oct 1, 2032
CompletionEst.
Oct 1, 2032
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites changed recruiting status (3 now recruiting, 3 now withdrawn, …)
Show 8 sites
  • UZ Leuven · Leuven, BelgiumActive, not recruiting→Recruiting
  • ZAHO Bonn Onkologische Praxis · Bonn, GermanyActive, not recruiting→Terminated
  • Universitätsklinikum Köln · Cologne, GermanyNot yet recruiting→Recruiting
  • SLK-Kliniken Heilbronn · Heilbronn, GermanyNot yet recruiting→Withdrawn
  • Universitätsklinik der Johannes-Gutenberg Universität Mainz · Mainz, GermanyActive, not recruiting→Withdrawn
  • Klinikum Dritter Orden · München, GermanyNot yet recruiting→Active, not recruiting
  • ASST Lecco - Ospedale A. Manzoni · Lecco, ItalyActive, not recruiting→Recruiting
  • AOU Cagliari · Monserrato, ItalyNot yet recruiting→Withdrawn
Oct 23, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • UZ Leuven · Leuven, BelgiumContact added (no phone or email listed)
  • SLK-Kliniken Heilbronn · Heilbronn, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Klinikum Dritter Orden · München, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • ASST Lecco - Ospedale A. Manzoni · Lecco, ItalyContact added (no phone or email listed)
  • AOU Cagliari · Monserrato, ItalyContact removed (no phone or email listed)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    8 sites changed recruiting status (3 now recruiting, 3 now withdrawn, …)
    Show 8 sites
    • UZ Leuven · Leuven, BelgiumActive, not recruiting→Recruiting
    • ZAHO Bonn Onkologische Praxis · Bonn, GermanyActive, not recruiting→Terminated
    • Universitätsklinikum Köln · Cologne, GermanyNot yet recruiting→Recruiting
    • SLK-Kliniken Heilbronn · Heilbronn, GermanyNot yet recruiting→Withdrawn
    • Universitätsklinik der Johannes-Gutenberg Universität Mainz · Mainz, GermanyActive, not recruiting→Withdrawn
    • Klinikum Dritter Orden · München, GermanyNot yet recruiting→Active, not recruiting
    • ASST Lecco - Ospedale A. Manzoni · Lecco, ItalyActive, not recruiting→Recruiting
    • AOU Cagliari · Monserrato, ItalyNot yet recruiting→Withdrawn
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • UZ Leuven · Leuven, BelgiumContact added (no phone or email listed)
    • SLK-Kliniken Heilbronn · Heilbronn, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Klinikum Dritter Orden · München, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • ASST Lecco - Ospedale A. Manzoni · Lecco, ItalyContact added (no phone or email listed)
    • AOU Cagliari · Monserrato, ItalyContact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05460000
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Collaborators
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Oct 11, 2024
Primary completion
Oct 1, 2032 (estimated)
Completion
Oct 1, 2032 (estimated)
Last update
Oct 23, 2026

Study contacts

Jessica Nguyen
Contact
jessica.nguyen@noggo.de
4930403686539
Jasmin Yamamoto
Contact
jasmin.yamamoto@noggo.de
4930403686532
Jalid Sehouli, Prof. Dr. med.
principal investigator · Lead coordinating investigator (LKP) according to AMG and representative of the sponsor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion